GEN Exclusives

More »
Readers Comments Back to Item »

BAC Targeting Biosimilar Market

1 Readers' Comments

Posted by: Lester Savit

12/11/2011

In October a federal court blocked market entry of a generic version of a complex active ingredient because of a patent on manufacturing (quality) control.  See www.lestersavit.com for a discussion of how this ruling reveals a new patent strategy for biosimilars.

  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?